drugset / Trial / NCT04007055

The Value of Screening for HPR in Patients Undergoing Lower Extremity Arterial Endovascular Interventions

NCT04007055

Phase 3 Terminated 31 enrolled Marissa Jarosinski
RandomizedParallel-groupOpen-labelScreening

Summary

This is a randomized controlled trial designed to evaluate the role of screening for and intervening on patients with high on treatment platelet reactivity undergoing lower extremity arterial endovascular interventions.

Timeline

Start
2019-08-09
Primary completion
2023-03-28
Completion
2024-03-28

Drugs

EvaluationDrugModalityDoseRoute
Subject Ticagrelor Small molecule 90 mg